We all know someone living with Alzheimer’s disease, whether a beloved parent, grandparent, a lifelong friend, a favorite teacher, or a neighbor.
We also all understand the toll that Alzheimer’s disease can take on caregivers, who can struggle for years to care for their affected loved one as they are no longer able to operate with full mental faculties.
In addition, the economic burden of Alzheimer’s disease on the United States is projected to skyrocket from $307 billion to $1.5 trillion annually by 2050 according to University of Southern California researchers.
What we do not have is a viable solution to treat this devastating disease.
I came to Anavex®Life Sciences in 2013 with the thought that this could change. The Company’s science and research aim has always been, and continues to be, to find the cause of neurodegenerative diseases, not just the consequences.Anavex® believes Alzheimer’s disease may be manifested through protein misfolding in the brain, which could turn into chronic cell distress, where the brain is not able to fend off the protein misfolding that could accumulate over time. The very high correlation of Alzheimer’s with age speaks to the manifestation of some constant aggression and probably the domino effect of the protein misfolding.
Chronic distress in the brain may have many sources. It could be caused by genetic factors, anxiety, lack of regular sleep, lack of physical exercise and poor diet. For example, we know today that all the things that are bad for the heart are also bad for the brain, such as a bad diet filled with high levels of fatty acids and/or too much sugar. Hence, some physicians regard Alzheimer’s as a “diabetes Type III.” The chronic cell stress may eventually cause the aggregation of Abeta or Tau, which are found in many Alzheimer’s patients. Interestingly, our drugs don’t target Abeta or Tau directly, however, have shown to reduce them. Hence, our drugs might be addressing the cause of the disease.
We, at Anavex®, are driven to find a solution to the largest and fastest growing therapeutic area, Alzheimer’s disease. We are also engaged to continue developing novel drug candidates for the treatments of central nervous system (CNS) diseases, pain and various types of cancers. Our Company has made important advances in the past year – from presenting successful Phase 1 data for the Company’s lead drug candidate, ANAVEX®2-73, to intelligently structuring and enrolling a state-of-the-art adaptive Phase 2a clinical trial of ANAVEX®2-73 and its combination with donepezil (Aricept®), known as ANAVEX®PLUS, for the treatment of Alzheimer’s disease.
With strategic expansion of our team through strong appointments to management, the Scientific Advisory Board and the Board of Directors, Anavex® is growing and actively advancing its robust pipeline. I strive to achieve our Company’s goals in a financially sound manner that can lead to value creation for the Company’s stakeholders. I also strive to find a potential solution to those affected by Alzheimer’s disease.
If you have questions or would like additional information about Anavex®, please do not hesitate to contact our investor relations team.
Christopher U. Missling, PhD
President and Chief Executive Officer